Direxion Daily S&P Biotech Bull 3x Shares Rating $127.71 +8.13 (+6.80%) (As of 11/1/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartHeadlinesHoldingsOwnershipRatings Direxion Daily S&P Biotech Bull 3x Shares Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.LABU Aggregate RatingModerate Buy2.76Holdings in LABU have an aggregate rating of Moderate Buy based on 630 analyst ratings issued in the past year covering 40 companies (46.4% of the portfolio).LABU Aggregate Price Target$163.3627.92% UpsideHigh Prediction$218.66Average Prediction$163.36Low Prediction$107.09Holdings in LABU have an aggregate price target of $163.36 and a range of $107.09 to $218.66 covering 40 companies (46.4% of the portfolio).LABU Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy11 Buy rating(s)Moderate Buy25 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Direxion Daily S&P Biotech Bull 3x Shares Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 40 LABU Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.90%ALNYAlnylam Pharmaceuticals$273.91+2.7%3.9357 of 5 stars2.75$294.50 7.5%24Analyst ForecastShort Interest ↑News Coverage1.89%UTHRUnited Therapeutics$374.02+0.0%4.5809 of 5 stars2.73$370.86 -0.8%15Earnings ReportAnalyst ForecastInsider SellingNews CoveragePositive News1.83%EXASExact Sciences$69.80+1.3%4.2415 of 5 stars2.94$80.64 15.5%16Upcoming EarningsAnalyst ForecastShort Interest ↑1.80%GILDGilead Sciences$89.51+0.8%4.9348 of 5 stars2.65$86.85 -3.0%23Upcoming EarningsAnalyst Forecast1.78%INCYIncyte$76.13+2.7%4.1207 of 5 stars2.38$76.74 0.8%21Earnings ReportAnalyst UpgradeShort Interest ↑News Coverage1.77%SRPTSarepta Therapeutics$123.29-2.2%4.9529 of 5 stars2.95$182.95 48.4%21Upcoming Earnings1.70%VRTXVertex Pharmaceuticals$471.12-1.0%3.4466 of 5 stars2.48$492.50 4.5%29Upcoming EarningsAnalyst Forecast1.67%VKTXViking Therapeutics$72.88+0.5%4.1445 of 5 stars3.09$108.60 49.0%111.67%INSMInsmed$68.32+1.5%3.8721 of 5 stars3.00$83.07 21.6%16Earnings ReportAnalyst ForecastNews Coverage1.66%ABBVAbbVie$203.55-0.2%4.8493 of 5 stars2.84$201.00 -1.3%19Earnings ReportDividend IncreaseAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage1.65%NTRANatera$124.16+2.6%2.9221 of 5 stars3.00$125.69 1.2%16Analyst ForecastInsider SellingNews Coverage1.65%NBIXNeurocrine Biosciences$122.21+1.6%4.9258 of 5 stars2.83$163.91 34.1%24Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage1.65%AMGNAmgen$319.22-0.3%4.5959 of 5 stars2.50$333.50 4.5%24Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst Revision1.63%BIIBBiogen$173.79-0.1%4.8404 of 5 stars2.62$262.83 51.2%26Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage1.45%REGNRegeneron Pharmaceuticals$843.60+0.6%4.8453 of 5 stars2.73$1,090.24 29.2%22Analyst ForecastAnalyst RevisionNews Coverage1.43%BMRNBioMarin Pharmaceutical$66.60+1.1%4.975 of 5 stars2.68$94.45 41.8%22Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage1.36%MRNAModerna$54.63+0.5%4.4772 of 5 stars2.10$94.65 73.3%20Upcoming Earnings1.18%CYTKCytokinetics$51.82+1.6%4.2609 of 5 stars2.73$83.93 62.0%15Upcoming EarningsInsider SellingShort Interest ↓1.06%CRSPCRISPR Therapeutics$50.76+9.4%2.7649 of 5 stars2.37$75.19 48.1%19Upcoming EarningsAnalyst Upgrade1.02%BPMCBlueprint Medicines$90.70+3.6%2.2097 of 5 stars2.70$120.39 32.7%20Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage0.98%HALOHalozyme Therapeutics$57.15+13.0%4.7142 of 5 stars2.60$61.00 6.7%10Analyst ForecastShort Interest ↑News CoverageGap UpHigh Trading Volume0.95%MDGLMadrigal Pharmaceuticals$319.58+23.2%3.9222 of 5 stars2.69$344.33 7.7%13Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading Volume0.95%RNAAvidity Biosciences$41.87-0.9%2.2262 of 5 stars3.00$63.22 51.0%9Analyst Forecast0.85%TGTXTG Therapeutics$26.90+7.3%4.7466 of 5 stars2.83$36.33 35.1%6Upcoming EarningsAnalyst ForecastNews Coverage0.84%KRYSKrystal Biotech$176.39+2.2%4.6407 of 5 stars3.00$196.75 11.5%9Upcoming EarningsPositive News0.82%RVMDRevolution Medicines$55.09+3.0%3.3345 of 5 stars3.08$56.75 3.0%12Upcoming Earnings0.79%IONSIonis Pharmaceuticals$38.76+1.0%4.2398 of 5 stars2.65$60.28 55.5%20Upcoming EarningsShort Interest ↓News Coverage0.78%ROIVRoivant Sciences$11.68+1.1%2.9589 of 5 stars2.90$17.39 48.9%100.76%PCVXVaxcyte$107.29+0.9%3.2559 of 5 stars3.00$147.50 37.5%7Upcoming EarningsPositive News0.72%BHVNBiohaven$50.88+2.3%2.639 of 5 stars3.07$61.92 21.7%140.72%ALKSAlkermes$26.47+3.0%4.89 of 5 stars2.50$34.90 31.8%10Short Interest ↓0.66%IOVAIovance Biotherapeutics$11.19+7.2%3.7609 of 5 stars2.89$22.33 99.6%9Upcoming Earnings0.65%EXELExelixis$34.12+2.8%4.6514 of 5 stars2.65$31.44 -7.8%20Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews CoverageHigh Trading Volume0.64%TWSTTwist Bioscience$41.57+3.0%3.5881 of 5 stars2.67$51.22 23.2%90.63%BBIOBridgeBio Pharma$25.48+8.8%4.5415 of 5 stars2.87$47.50 86.4%15Upcoming Earnings0.62%ADMAADMA Biologics$19.37+18.8%2.606 of 5 stars3.25$15.50 -20.0%4Upcoming EarningsShort Interest ↓Gap UpHigh Trading Volume0.58%CRNXCrinetics Pharmaceuticals$56.69+1.3%3.0327 of 5 stars2.91$68.55 20.9%11Negative News0.57%GERNGeron$4.113.933 of 5 stars3.00$6.94 69.0%10Upcoming Earnings0.56%DYNDyne Therapeutics$28.74-0.4%3.3193 of 5 stars3.00$50.60 76.1%10Upcoming Earnings0.56%APLSApellis Pharmaceuticals$27.98+2.6%4.5187 of 5 stars2.78$65.41 133.8%19Upcoming EarningsAnalyst UpgradeAnalyst RevisionGap Up This page (NYSEARCA:LABU) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Direxion Daily S&P Biotech Bull 3x Shares Please log in to your account or sign up in order to add this asset to your watchlist. Share Direxion Daily S&P Biotech Bull 3x Shares With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
